It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INCR’s FA Score shows that 1 FA rating(s) are green whileKMDA’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INCR’s TA Score shows that 5 TA indicator(s) are bullish while KMDA’s TA Score has 4 bullish TA indicator(s).
INCR (@Pharmaceuticals: Other) experienced а +2.88% price change this week, while KMDA (@Pharmaceuticals: Other) price change was -5.27% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.61%. For the same industry, the average monthly price growth was +1.68%, and the average quarterly price growth was -9.09%.
INCR is expected to report earnings on Apr 07, 2025.
KMDA is expected to report earnings on Feb 12, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
INCR | KMDA | INCR / KMDA | |
Capitalization | 124M | 306M | 41% |
EBITDA | 25.8M | 22.4M | 115% |
Gain YTD | 10.870 | -6.046 | -180% |
P/E Ratio | 22.52 | 37.43 | 60% |
Revenue | 415M | 143M | 290% |
Total Cash | 103M | 55.6M | 185% |
Total Debt | 163M | 8.82M | 1,848% |
INCR | KMDA | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 79 | |
PRICE GROWTH RATING 1..100 | 57 | 50 | |
P/E GROWTH RATING 1..100 | 4 | 96 | |
SEASONALITY SCORE 1..100 | 50 | 43 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KMDA's Valuation (67) in the Biotechnology industry is in the same range as INCR (69) in the Servicestothe Health Industry industry. This means that KMDA’s stock grew similarly to INCR’s over the last 12 months.
KMDA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as INCR (100) in the Servicestothe Health Industry industry. This means that KMDA’s stock grew similarly to INCR’s over the last 12 months.
KMDA's SMR Rating (79) in the Biotechnology industry is in the same range as INCR (94) in the Servicestothe Health Industry industry. This means that KMDA’s stock grew similarly to INCR’s over the last 12 months.
KMDA's Price Growth Rating (50) in the Biotechnology industry is in the same range as INCR (57) in the Servicestothe Health Industry industry. This means that KMDA’s stock grew similarly to INCR’s over the last 12 months.
INCR's P/E Growth Rating (4) in the Servicestothe Health Industry industry is significantly better than the same rating for KMDA (96) in the Biotechnology industry. This means that INCR’s stock grew significantly faster than KMDA’s over the last 12 months.
INCR | KMDA | |
---|---|---|
RSI ODDS (%) | 2 days ago87% | 3 days ago83% |
Stochastic ODDS (%) | 2 days ago86% | 2 days ago61% |
Momentum ODDS (%) | 2 days ago79% | 2 days ago71% |
MACD ODDS (%) | 2 days ago83% | 2 days ago76% |
TrendWeek ODDS (%) | 2 days ago80% | 2 days ago69% |
TrendMonth ODDS (%) | 2 days ago75% | 2 days ago69% |
Advances ODDS (%) | 10 days ago74% | 10 days ago68% |
Declines ODDS (%) | 6 days ago82% | 2 days ago69% |
BollingerBands ODDS (%) | N/A | 2 days ago76% |
Aroon ODDS (%) | 2 days ago79% | 2 days ago53% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
SSBIX | 13.21 | N/A | N/A |
State Street Balanced Index K | |||
PGFIX | 82.46 | N/A | N/A |
Virtus Silvant Focused Growth Inst | |||
BILSX | 9.60 | -0.02 | -0.21% |
BlackRock U.S. Insights Lon/Shr Eq Ins | |||
CLSYX | 19.89 | -0.12 | -0.60% |
Columbia International Div Inc Inst3 | |||
BTEKX | 76.45 | -0.57 | -0.74% |
BlackRock Technology Opportunities K |
A.I.dvisor tells us that INCR and KMDA have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INCR and KMDA's prices will move in lockstep.
Ticker / NAME | Correlation To INCR | 1D Price Change % | ||
---|---|---|---|---|
INCR | 100% | N/A | ||
KMDA - INCR | 31% Poorly correlated | -0.86% | ||
SNDL - INCR | 25% Poorly correlated | +4.17% | ||
DVAX - INCR | 23% Poorly correlated | +0.39% | ||
SUPN - INCR | 23% Poorly correlated | -0.74% | ||
QNTM - INCR | 23% Poorly correlated | +1.93% | ||
More |
A.I.dvisor tells us that KMDA and NXSCF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and NXSCF's prices will move in lockstep.
Ticker / NAME | Correlation To KMDA | 1D Price Change % | ||
---|---|---|---|---|
KMDA | 100% | -0.86% | ||
NXSCF - KMDA | 27% Poorly correlated | N/A | ||
SGIOY - KMDA | 27% Poorly correlated | -0.43% | ||
INCR - KMDA | 27% Poorly correlated | N/A | ||
ACET - KMDA | 22% Poorly correlated | -0.75% | ||
RDY - KMDA | 22% Poorly correlated | -1.43% | ||
More |